Avandia Panel Wants Another Trial: Pipe Dream Or Post-market Benchmark?

Designed with complex, multi-variate statistics, an observational trial could determine the CV risk of rosiglitazone compared to other diabetes drugs, an advisory committee member suggests during the latest assessment of Avandia.